Should I buy or sell Processa Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PCSA shares. View PCSA analyst ratings or view top-rated stocks .

How have PCSA shares performed in 2024?

Processa Pharmaceuticals' stock was trading at $6.6920 at the start of the year. Since then, PCSA shares have decreased by 76.7% and is now trading at $1.56. View the best growth stocks for 2024 here .

When is Processa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PCSA earnings forecast .

How were Processa Pharmaceuticals' earnings last quarter?

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced its earnings results on Friday, November, 12th. The company reported ($3.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.60) by $0.20. During the same period last year, the firm posted ($11.00) EPS.

When did Processa Pharmaceuticals' stock split?

Shares of Processa Pharmaceuticals reverse split on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Processa Pharmaceuticals?

Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PCSA

Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free PCSA Stock Alerts

$1.56

-0.10 (-6.02%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.50
▼
$1.67
50-Day Range: $1.52
▼
$2.99
52-Week Range: $1.40
▼
$18.00

Volume: 63,119 shs
Average Volume: 1.40 million shs
Market Capitalization: $4.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Processa Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Processa Pharmaceuticals Stock (NASDAQ:PCSA)

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

PCSA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PCSA Stock News Headlines

April 11, 2024 | msn.com

U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%

April 11, 2024 | finance.yahoo.com

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 7, 2024 | finance.yahoo.com

Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k

March 28, 2024 | nz.finance.yahoo.com

Eva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home mom

March 28, 2024 | globenewswire.com

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

March 25, 2024 | globenewswire.com

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

February 24, 2024 | msn.com

Processa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 21, 2024 | finance.yahoo.com

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

February 21, 2024 | globenewswire.com

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

February 14, 2024 | finance.yahoo.com

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

February 14, 2024 | globenewswire.com

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

February 6, 2024 | markets.businessinsider.com

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

February 6, 2024 | investing.com

Processa Pharmaceuticals Inc (PCSA)

February 1, 2024 | finance.yahoo.com

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

February 1, 2024 | msn.com

Processa Pharmaceuticals Announces Offering Pricing Details

January 27, 2024 | marketwatch.com

Processa Pharmaceuticals Shares Drop 24% After Pricing Offering

January 26, 2024 | msn.com

Processa Pharmaceuticals prices discounted stock and warrants offering to raise $7M

January 26, 2024 | msn.com

What's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?

January 26, 2024 | finance.yahoo.com

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

January 25, 2024 | marketwatch.com

Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment

January 25, 2024 | finance.yahoo.com

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

January 20, 2024 | msn.com

Processa Pharmaceuticals Expands NGC-Cap Cancer Program

January 19, 2024 | finanznachrichten.de

Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

January 19, 2024 | msn.com

Why Processa Pharmaceuticals (PCSA) Stock Is Skyrocketing

January 19, 2024 | finance.yahoo.com

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

See More Headlines

Receive PCSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PCSA
CUSIP: N/A
CIK: 1533743
Web: www.processapharmaceuticals.com
Phone: (443) 776-3133
Fax: 443-288-4420
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -141.42%
Return on Assets: -122.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.70
Quick Ratio: 7.70

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.05 per share
Price / Book: 0.39

Miscellaneous

Outstanding Shares: 2,860,000
Free Float: 2,222,000
Market Cap: $4.46 million
Optionable: Not Optionable
Beta: 0.53

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. George K. Ng Esq. (Age 50)
J.D., CEO & Director
Comp: $400.27k
Dr. David Young Ph.D. (Age 71)
Pharm.D., Co-Founder, President of Research and Development & Director
Comp: $160.2k
Dr. Sian E. Bigora Ph.D. (Age 64)
Pharm.D., Co-Founder and Chief Development & Regulatory Officer
Comp: $184.87k
Mr. James H. Stanker (Age 66)
Chief Financial Officer
Comp: $160.2k
Mr. Patrick Lin (Age 59)
Co-Founder, Chief Business & Strategy Officer
Comp: $117.15k
Ms. Wendy J. Guy (Age 60)
Co-Founder, Chief Administrative Officer & Corporate Secretary
Comp: $94.19k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Processa Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PCSA shares.
View PCSA analyst ratings or view top-rated stocks.
How have PCSA shares performed in 2024?: Processa Pharmaceuticals' stock was trading at $6.6920 at the start of the year. Since then, PCSA shares have decreased by 76.7% and is now trading at $1.56.
View the best growth stocks for 2024 here.
When is Processa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PCSA earnings forecast.
How were Processa Pharmaceuticals' earnings last quarter?: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced its earnings results on Friday, November, 12th. The company reported ($3.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.60) by $0.20. During the same period last year, the firm posted ($11.00) EPS.

When did Processa Pharmaceuticals' stock split?: Shares of Processa Pharmaceuticals reverse split on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of Processa Pharmaceuticals?: Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCSA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis

About Processa Pharmaceuticals Stock (NASDAQ:PCSA)

PCSA Stock Price History

PCSA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PCSA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info